DRAFT · NOT ISSUED

LABDOC

Independent Verification

TEST REPORT

CERTIFICATE OF ANALYSIS

REPORT ID	SAMPLE RECEIVED	DATE TESTED
LD-VC6P	21 OCTOBER 2026	02 NOVEMBER 2026

01 / SAMPLE DETAILS

Tesamorelin

Lyophilized Powder (Vial)

Client	**Sydney Peptides**
Company	**Sydney Peptides**
Origin	**S&P**
Label claim	**10 mg**



VIAL AS RECEIVED LD-VC6P

TESTS REQUESTED

Identity (LC-MS), purity (HPLC) and content (HPLC) of a peptide vial or vials.

02 / RESULTS

CONTENT (HPLC)	PURITY (HPLC)	IDENTITY (LC-MS)
9.16 mg	98.75%	Confirmed
91.6% of claim		

DETAILED FINDINGS

Label claim	**10 mg**
Content (HPLC)	**9.16 mg (91.6%)**
Purity (HPLC)	**98.75%**
Identity (LC-MS)	**Confirmed**

OVERALL ASSESSMENT — **Pass**

03 / ANALYSIS & VERIFICATION

Analysis by **Samir Dhakal, Apex Labs**

Analysis conducted: 02 NOVEMBER 2026

Report Compiled by **Lab Doc Aus Pty Ltd**, 02 NOVEMBER 2026

This report covers the tested sample only. LabDoc does not sell, supply or endorse any product or supplier, and this report is not a statement that any product is lawful, safe or suitable for use.